ConductScience.org, home

Paper35148751

Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.

Huang L and 10 others. Mol Cancer, 2022. Cited by 347 papers, by iCite.

Cite this record

ConductScience Library. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Papers, record 35148751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35148751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
PubMed
Journal
Mol Cancer
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
347
iCite
Relative citation ratio, by iCite
25.2
iCite
Revised in PubMed
2022-04-05
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huang LLanxiang
2Rong YYuan
3Tang XXuan
4Yi KKezhen
5Qi PPeng
6Hou JJinxuan
7Liu WWeihuang
8He YYuan
9Gao XXing
10Yuan CChunhui
11Wang FFubing

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Cancer VaccinesMajor topic
ExosomesMajor topic
VaccinesMajor topic
Animals
Cell Line, Tumor
Dendritic Cells
Female
Humans
Leukocytes, Mononuclear
Mice
Tumor Microenvironment

Source PubMed

Download CSV of topics

References58

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127558906Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models.Nanomedicine (Lond)2016https://conductscience.org/library/papers/27558906PubMed
232661307Gold/alpha-lactalbumin nanoprobes for the imaging and treatment of breast cancer.Nat Biomed Eng2020https://conductscience.org/library/papers/32661307PubMed
332303573IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer.Sci Immunol2020https://conductscience.org/library/papers/32303573PubMed
432941949CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.Cancer Lett2020https://conductscience.org/library/papers/32941949PubMed
523569327Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells.J Exp Med2013https://conductscience.org/library/papers/23569327PubMed
629224780A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.Cell2018https://conductscience.org/library/papers/29224780PubMed
729054784Developing a xenograft human tumor model in immunocompetent mice.Cancer Lett2018https://conductscience.org/library/papers/29054784PubMed
832764681Antitumour dendritic cell vaccination in a priming and boosting approach.Nat Rev Drug Discov2020https://conductscience.org/library/papers/32764681PubMed
929950349Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.Clin Cancer Res2018https://conductscience.org/library/papers/29950349PubMed
1031031762Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.Front Immunol2019https://conductscience.org/library/papers/31031762PubMed
1131467405Dendritic cells in cancer immunology and immunotherapy.Nat Rev Immunol2020https://conductscience.org/library/papers/31467405PubMed
1227939063Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.Lancet2017https://conductscience.org/library/papers/27939063PubMed
1317187072Calreticulin exposure dictates the immunogenicity of cancer cell death.Nat Med2007https://conductscience.org/library/papers/17187072PubMed
1425001465Therapeutic vaccines for cancer: an overview of clinical trials.Nat Rev Clin Oncol2014https://conductscience.org/library/papers/25001465PubMed
1532210954Engineered Tumor-Derived Extracellular Vesicles: Potentials in Cancer Immunotherapy.Front Immunol2020https://conductscience.org/library/papers/32210954PubMed
1626014293Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.J Clin Oncol2015https://conductscience.org/library/papers/26014293PubMed
1731912821Photothermal therapy-induced immunogenic cell death based on natural melanin nanoparticles against breast cancer.Chem Commun (Camb)2020https://conductscience.org/library/papers/31912821PubMed
1824188672Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.Immunotherapy2013https://conductscience.org/library/papers/24188672PubMed
1931853056Tumor organoid-T-cell coculture systems.Nat Protoc2020https://conductscience.org/library/papers/31853056PubMed
2026936504Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.Sci Transl Med2016https://conductscience.org/library/papers/26936504PubMed

See all 58 referencesDownload CSV of references

Cited by236

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 347 citations.

PMIDTitleJournalYearIn PapersSource
42936663Extracellular Vesicles in Breast Cancer: Immunomodulation, Biomarkers, and Therapy.Int J Nanomedicine2026https://conductscience.org/library/papers/42936663PubMed
42913016An in situ forming immunomodulatory hydrogel reinvigorates exhausted CD8+ T cells via preserving their mitochondrial fitness.Sci Adv2026https://conductscience.org/library/papers/42913016PubMed
42866611Engineered exosomes for breast cancer immunotherapy: Emerging strategies and translational potential.Biochem Biophys Rep2026https://conductscience.org/library/papers/42866611PubMed
42824691Biomimetic nano-in-gel vaccine platform with spatiotemporal co-delivery capacity for DC maturation against immunosuppressive tumors.Int J Pharm X2026https://conductscience.org/library/papers/42824691PubMed
42789159Current status of extracellular vesicle technology in industrialization and commercialization.Discov Nano2026https://conductscience.org/library/papers/42789159PubMed
42771161Smart drug delivery systems for immunotherapeutic agents: focus on biological/biogenic platform-based intelligent delivery in cancer immunotherapy.Drug Deliv Transl Res2026https://conductscience.org/library/papers/42771161PubMed
42733592Construction and application of mammary and breast cancer organoids.Cell Insight2026https://conductscience.org/library/papers/42733592PubMed
42711596Extracellular vesicles for next-gen therapeutics and drug delivery.Mol Biomed2026https://conductscience.org/library/papers/42711596PubMed
42630463Advances in the Research and Development of Breast Cancer Organoids.Oncol Res2026https://conductscience.org/library/papers/42630463PubMed
42500576Crosstalk between Extracellular Vesicles and the Tumor Microenvironment: Mechanistic Insights and Therapeutic Opportunities.Oncol Res2026https://conductscience.org/library/papers/42500576PubMed
42454198A multidimensional landscape of extracellular vesicle-mediated tumor drug resistance: mechanisms, biomarkers, engineered drug delivery, and clinical translation.Extracell Vesicles Circ Nucl Acids2026https://conductscience.org/library/papers/42454198PubMed
42434728A multi-level charged micelle-based microneedle transdermal system for immunosuppressive tumor microenvironment regulation and synergistic therapy.Mater Today Bio2026https://conductscience.org/library/papers/42434728PubMed
42325249Chimeric biohybrid nanovesicles induce immunogenic cell death for targeted and immune-potentiated glioblastoma therapy.Asian J Pharm Sci2026https://conductscience.org/library/papers/42325249PubMed
42273693Exosomes in inflammatory tissue injury: key pathogenic factors and promising therapeutic agents.Front Immunol2026https://conductscience.org/library/papers/42273693PubMed
42266701Overcoming immunotherapy resistance in triple-negative breast cancer: a critical review of mast cell plasticity, metabolic reprogramming, and organoid models.Front Immunol2026https://conductscience.org/library/papers/42266701PubMed
42193932The Organoid Decade: Leveraging 3D Patient-Derived Organoids to Bridge the Translational Gap in Triple-Negative Breast Cancer: A Systematic Review.Cells2026https://conductscience.org/library/papers/42193932PubMed
42133100The synergistic applications of organoids and exosomes in disease modeling and disease treatment.Mol Biol Rep2026https://conductscience.org/library/papers/42133100PubMed
42124939Establishment of Breast Cancer Organoids: A Systematic Review and Meta-Analysis.Int J Breast Cancer2026https://conductscience.org/library/papers/42124939PubMed
42063127The neuroimmune axis in breast cancer: from mechanistic insights to clinical applications.BMC Med2026https://conductscience.org/library/papers/42063127PubMed
42023220From immune desert to hot tumor: the tripartite synergy of tumor microenvironment-exosomes-immunogenic cell death in pioneering solutions.Front Immunol2026https://conductscience.org/library/papers/42023220PubMed

See all 236 cited byDownload CSV of cited by

Genes33

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APELA100506013PubTator's text mininghttps://conductscience.org/library/genes/100506013NCBI Gene
CALR811PubTator's text mininghttps://conductscience.org/library/genes/811NCBI Gene
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836NCBI Gene
CAT847PubTator's text mininghttps://conductscience.org/library/genes/847NCBI Gene
CD1C911PubTator's text mininghttps://conductscience.org/library/genes/911NCBI Gene
CD20930835PubTator's text mininghttps://conductscience.org/library/genes/30835NCBI Gene
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD69969PubTator's text mininghttps://conductscience.org/library/genes/969NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CSF21437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
ELANE1991PubTator's text mininghttps://conductscience.org/library/genes/1991NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
F22147PubTator's text mininghttps://conductscience.org/library/genes/2147NCBI Gene
GAPDH2597PubTator's text mininghttps://conductscience.org/library/genes/2597NCBI Gene
GZMB3002PubTator's text mininghttps://conductscience.org/library/genes/3002NCBI Gene
HLA-A3105PubTator's text mininghttps://conductscience.org/library/genes/3105NCBI Gene
HLA-C3107PubTator's text mininghttps://conductscience.org/library/genes/3107NCBI Gene
HMGB13146PubTator's text mininghttps://conductscience.org/library/genes/3146NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene

See all 33 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35148751

GET https://conductscience.org/api/papers/v1/35148751/references?page=2